| Biotechnology Industry | Healthcare Sector | Mr. Chuang Wang CEO | HKEX Exchange | KYG2129W1380 ISIN |
| Hong Kong Country | 39 Employees | - Last Dividend | 23 Aug 2023 Last Split | - IPO Date |
China Regenerative Medicine International Limited operates as an investment holding company primarily in Hong Kong and the People's Republic of China. It specializes in the production and sale of healthcare products and services, focusing on the development of treatments and solutions that encourage the body's natural regenerative processes. The enterprise has undergone significant transformations since its establishment in 1995, including a name change from China Bio-Med Regeneration Technology Limited to its current designation in March 2015. With its headquarters situated in Tsim Sha Tsui, Hong Kong, the company continues to pioneer in the field of regenerative medicine, promoting health and wellness across varied demographics.
China Regenerative Medicine International Limited offers a comprehensive suite of healthcare products and services tailored to enhance overall well-being and address specific health issues. Their offerings include: